Development of a novel vaccine delivery system based on Gantrez nanoparticles
Gómez S (1), Gamazo C (1), San Roman B (1), Vauthier C (1), Ferrer M (2), Irachel JM.(1)
(1) Adjuvant Unit, Department of Pharmaceutical Technology and Microbiology, University of Navarra, 31080 Pamplona, Spain
(2) Allergy Department, Clínica Universitaria, 31080 Pamplona, Spain
The adjuvant capacity of a novel vaccine vector "Gantrez-nanoparticles" (NP) towards coated or encapsulated ovalbumin (OVA) was investigated. OVA nanoparticles were prepared by a solvent displacement method previously described.
The protein was incorporated during the manufacturing process (OVA-encapsulated nanoparticles) or after the preparation (OVA-coated nanoparticles). The mean size of the different nanoparticle formulations was lower than 300 nm, and the OVA content ranged approximately from 67 microg/mg nanoparticles (for OVA-coated nanoparticles) to 30 microg/mg nanoparticles (for OVA-encapsulated nanoparticles). All the OVA-NP formulations were capable of amplifying the antibodies titres (IgG1 and IgG2a) in mice after a single subcutaneous inoculation with respect free OVA or OVA adsorbed to Alum. Furthermore, the elicited response was, for some formulations, predominantly Th1 subtype.
Thus, the formulation that contained mainly the antigen inside, and with a low concentration of cross-linking agent, displayed the best potential to induce a Th1 response after 35 days post-immunisation.
These results are highly suggestive for the use of Gantrez nanoparticles as an efficient antigen delivery system, especially when a long lasting Th1 cytokine response is required.
CITATION J Nanosci Nanotechnol. 2006 Sep-Oct;6(9-10):3283-9